Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AF-16 in cerebral oedema after traumatic brain injury (open-label historical cohort study)
2021-006694-39Phase 2Completed
- Sponsor
- Lantmännen AS-Faktor
- Start
- Mar 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of AF-16 in cerebral edema and traumatic brain injury (TBI) (2 arms), sponsored by Lantmännen AS-Faktor. Primary endpoint: Primary safety and tolerability endpoints. Started Mar 2022; status: completed.
02
Drugs
AF-16
03
Conditions
cerebral edematraumatic brain injury (TBI)
Beyond the preview
Go deeper on 2021-006694-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006694-39.